These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3243399)

  • 21. The need and value of routine screening of all pregnant women for hepatitis B surface antigen.
    Capar M; Kosić-Andrasević V; Popić G; Raguz L; Mahuĺja-Stamenković V; Zuzek A; Dujmović A; Milevoj-Razem M; Ljutić S
    Acta Med Croatica; 1995; 49(4-5):161-4. PubMed ID: 8630446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Viral hepatitis B and the antigen carrier state in tuberculosis patients].
    Vil'derman AM; Marchenko IuG; Gul'pe PA; Mel'nichuk AE; Shtefanaru LK
    Probl Tuberk; 1981 Jun; (6):43-7. PubMed ID: 7279909
    [No Abstract]   [Full Text] [Related]  

  • 23. [Strategies in the therapy of hepatitis B surface antigen (HBsAg-)-positive chronic hepatitis].
    Hess G; Meyer zum Büschenfelde KH
    Dtsch Med Wochenschr; 1986 Dec; 111(50):1933-7. PubMed ID: 2430769
    [No Abstract]   [Full Text] [Related]  

  • 24. [Relationship of the incidence of the HBsAg carrier state to ABO and Rhesus blood group systems].
    Khersonskaia RIa; Rogotskaia LT
    Vrach Delo; 1981 Sep; (9):119-21. PubMed ID: 6795822
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical aspects and diagnosis of chronic viral hepatitis B].
    Grigor'ev PIa; Iakovenko EP; Zakharov VN; Saiapina ES; Shubina GI
    Klin Med (Mosk); 1984 Feb; 62(2):5-10. PubMed ID: 6708442
    [No Abstract]   [Full Text] [Related]  

  • 26. Prevalence of hepatitis B e antigen in pregnant women and patients with liver disease.
    Gill HH; Majumdar PD; Dhunjibhoy KR; Desai HG
    J Assoc Physicians India; 1995 Apr; 43(4):247-8. PubMed ID: 8713262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of lipid metabolism in patients with chronic, active hepatitis (HBsAg positive)].
    Kryska A; Juszczyk J; Bereszyńska I; Krajewski P
    Pol Tyg Lek; 1991 Feb 18-Mar 4; 46(8-10):159-60. PubMed ID: 1845736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Investigation of hemodialysis patients in terms of the presence of occult hepatitis B].
    Altindiş M; Uslan I; Cetinkaya Z; Yüksel S; Ciftçi IH; Demirtürk N; Ozdemir M; Arslan F; Aktepe OC
    Mikrobiyol Bul; 2007 Apr; 41(2):227-33. PubMed ID: 17682709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Asymptomatic carriers of HBsAg: is a follow-up necessary?].
    Vignote ML; Gómez-Camacho F; Poyato A; González R; Palomo D; Hervás A; Peña J; Miño G
    Rev Esp Enferm Dig; 1995 Oct; 87(10):715-9. PubMed ID: 8519537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of hepatitis B virus carriers with normal transaminases levels.
    Koçak N; Ozen H; Yüce A; Gürakan F
    Turk J Pediatr; 1998; 40(3):365-72. PubMed ID: 9763900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic asymptomatic HBSAg carriers: histologic abnormalities and diagnostic and prognostic value of serologic markers of the HBV.
    De Franchis R; D'Arminio A; Vecchi M; Ronchi G; Del Ninno E; Parravicini A; Ferroni P; Zanetti AR
    Gastroenterology; 1980 Sep; 79(3):521-7. PubMed ID: 7429112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management of HBs antigen carriers].
    Kashiwagi S
    Fukuoka Igaku Zasshi; 1989 Aug; 80(8):418-22. PubMed ID: 2583653
    [No Abstract]   [Full Text] [Related]  

  • 33. Infection with the delta agent in chronic HBsAg carriers.
    Smedile A; Dentico P; Zanetti A; Sagnelli E; Nordenfelt E; Actis GC; Rizzetto M
    Gastroenterology; 1981 Dec; 81(6):992-7. PubMed ID: 7286594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fatal hepatitis B in early infancy: the importance of identifying HBsAg-positive pregnant women and providing immunoprophylaxis to their newborns.
    Delaplane D; Yogev R; Crussi F; Shulman ST
    Pediatrics; 1983 Aug; 72(2):176-80. PubMed ID: 6683400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The prognostic significance of quantitative HBsAG determination in acute hepatitis B].
    Joller-Jemelka HI; Pfister HF; Grob PJ
    Schweiz Med Wochenschr; 1985 Sep; 115(37):1249-56. PubMed ID: 3903984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of hepatitis B virus DNA over a wide range from serum for studying viral replicative activity in response to treatment and in recurrent infection.
    Ranki M; Schätzl HM; Zachoval R; Uusi-Oukari M; Lehtovaara P
    Hepatology; 1995 Jun; 21(6):1492-9. PubMed ID: 7768492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Changes in laboratory test values after physical exercise in symptom-free HBsAg carriers (author's transl)].
    Veselý V; Pribil M; Pribilová A; Kulich V
    Cas Lek Cesk; 1980 Sep; 119(36-37):975-7. PubMed ID: 7438171
    [No Abstract]   [Full Text] [Related]  

  • 38. [A follow-up study on HBsAg carriers and factors affecting negative-conversion].
    Hong DQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 1984 Jan; 18(1):32-4. PubMed ID: 6468123
    [No Abstract]   [Full Text] [Related]  

  • 39. [106 cases of HBsAg carriers and factors influencing the prognosis: a follow-up study of 7-12 years].
    Hong DQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 1985 Aug; 6(4):223-6. PubMed ID: 4092225
    [No Abstract]   [Full Text] [Related]  

  • 40. What should we clinicians do for healthy, asymptomatic, HBsAg-positive carriers?
    McMahon BJ
    Hepatology; 1993 Oct; 18(4):1014-6. PubMed ID: 8406347
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.